NR1H4 and metabolic dysfunction-associated steatohepatitis: Clinical improvements including lower gamma-glutamyl transferase levels with FXR agonist therapy in NASH fibrosis48 could involve FXR-mediated upregulation of pericentral BSEP to alleviate microcholestasis.